Rodrigo Moreira da Silva

Rodrigo Moreira da Silva

Auto-generated profile, based on publicly available information

Rodrigo Moreira da Silva

NPPNS, Department of Biomolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JGJulia M. Gauglitz
Julia M. Gauglitz
KWKiana A. West
Kiana A. West
WBWout Bittremieux
Wout Bittremieux
CWCandace L. Williams
Candace L. Williams
KWKelly C. Weldon
Kelly C. Weldon
PDPieter C. Dorrestein
Pieter C. Dorrestein

1 April 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
LPLuísa Perin
Luísa Perin
RSRodrigo Moreira da Silva
Rodrigo Moreira da Silva
KFKátia da Silva Fonseca
Kátia da Silva Fonseca
JCJamille Mirelle de Oliveira Cardoso
Jamille Mirelle de Oliveira Cardoso
FMFernando Augusto Siqueira Mathias
Fernando Augusto Siqueira Mathias
CCclaudia carneiro
claudia carneiro
Specific chemotherapy using benznidazole (BNZ) for Chagas disease during the chronic stage is controversial due to its limited efficacy and toxic effects. Although BNZ has been used to treat Chagas disease since the 1970s, few studies about the biodistribution of this drug exist. In this study, BNZ tissue biodistribution in a murine model and its pharmacokinetic profile in plasma were monitored. A bioanalytical high-performance liquid chromatography method with a UV detector (HPLC-UV) was developed and validated according to the European Medicines Agency for quantification of BNZ in organs and plasma samples prepared by liquid-liquid extraction using ethyl acetate. The developed method was linear in the BNZ concentration, which ranged from 0.1 to 100.0 μg/ml for plasma, spleen, brain, colon, heart, lung, and kidney and from 0.2 to 100.0 μg/ml for liver. Validation assays demonstrated good stability for BNZ under all conditions evaluated. Pharmacokinetic parameters confirmed rapid, but low, absorption of BNZ after oral administration. Biodistribution assays demonstrated different maximum concentrations in organs and similar times to maximum concentration and mean residence times, with means of 40 min and 2.5 h, respectively. Therefore, the biodistribution of BNZ is extensive, reaching organs such as the heart and colon, which are the most relevant organs affected by Trypanosoma cruzi infection, and also the spleen, brain, liver, lungs, and kidneys. Simultaneous analyses of tissues and plasma indicated high BNZ metabolism in the liver. Our results suggest that low bioavailability, instead of inadequate biodistribution, could be responsible for therapeutic failure during the chronic phase of Chagas disease.

1 June 2019 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
FFFranciele S. Fonseca
Franciele S. Fonseca
DCDaniel Carrão
Daniel Carrão
NANayara C.P. de Albuquerque
Nayara C.P. de Albuquerque
VNViviani Nardini
Viviani Nardini
LDLuís G. Dias
Luís G. Dias
Anderson R. M. De OliveiraAnderson R. M. De Oliveira
Anderson R. M. De Oliveira

7 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JXJacinthia Beatriz Xavier-Santos
Jacinthia Beatriz Xavier-Santos
JPJúlia Gabriela Ramos Passos
Júlia Gabriela Ramos Passos
JGJacyra Antunes Santos Gomes
Jacyra Antunes Santos Gomes
JCJoelly Vilaine Cavalcante Cruz
Joelly Vilaine Cavalcante Cruz
JAJovelina Samara Ferreira Alves
Jovelina Samara Ferreira Alves
MPMatheus Pedrosa
Matheus Pedrosa
The growing use of phytotherapy in clinical practice arouses interest in studies using medicinal plants as active ingredients for new medicines. Ipomoea pes-caprae has a wide medicinal use in the treatment of inflammatory disorders, skin wounds, stings, and painful rheumatic processes. Assayed in this study are the physicochemical characterization of a gel developed with this extract and the evaluation of its anti-inflammatory and healing efficacy, in addition to its antiedematogenic action on Bothrops snake envenoming in mice. The qualitative and quantitative analyses of the hydroethanolic extract by mass spectrometry showed 18 phenolic compounds, highlighting a high content of chlorogenic acid (0.92 µg/g), neochlorogenic acid (6.07 µg/g), and isochlorogenic acid (0.80 µg/g) compounds. The formulation was stable in relation to the physical-chemical characteristics during the time of analysis and was considered safe for topical treatment in animals, causing no skin irritation. Although the results have shown an absence of activity in the model of ear edema induced by croton oil (acute inflammation), the herbal gel efficiently inhibited carrageenan paw edema and chronic ear edema induced by multiple applications of croton oil, which may indicate the possible performance under the kinin pathway such as bradykinin, histamine, and serotonin. Wound healing in the group treated with the I. pes-caprae gel was accelerated compared with the placebo group, also confirmed through histological data. Edema induced by Bothrops erythromelas snake venom was efficiently reduced in the treatment with I. pes-caprae gel associated with the antibothropic-crotalic serum, whereas the antivenom alone was not effective. This approach presents a promising formulation based on I. pes-caprae with potential therapeutic use for inflammatory disorders.

1 October 2019 in Toxicology Letters
Verified
Journal Article
Closed access
DCDaniel Carrão
Daniel Carrão
MHMaísa Daniela Habenchus
Maísa Daniela Habenchus
NANayara Cristina Perez de Albuquerque
Nayara Cristina Perez de Albuquerque
RSRodrigo Moreira da Silva
Rodrigo Moreira da Silva
Norberto Peporine LopesNorberto Peporine Lopes
Norberto Peporine Lopes
Anderson R. M. De OliveiraAnderson R. M. De Oliveira
Anderson R. M. De Oliveira

1 June 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
RSRodrigo Moreira da Silva
Rodrigo Moreira da Silva
LOLíliam Teixeira Oliveira
Líliam Teixeira Oliveira
NBNeila Márcia Silva Barcellos
Neila Márcia Silva Barcellos
JSJacqueline de Souza
Jacqueline de Souza
Marta de LanaMarta de Lana
Marta de Lana
A combination of drugs in experimental chemotherapy of Chagas' disease may increase the effectiveness of treatment. To evaluate the possible mechanisms that influence the improvement of therapy, we investigated the pharmacokinetic interaction between benznidazole and itraconazole in a murine model treated orally with single doses of 5 mg of each compound separately or together. Blood samples from treated mice were collected at different intervals for 48 h, and a high-performance liquid chromatography (HPLC)-UV method was used to quantify both drugs in the plasma. A decrease of 1.5-fold in the maximum drug concentration in the plasma ( C max ) and an increase of 2.66-fold in the volume of distribution ( V ) and 7.5-fold in the elimination half-life ( t 1/2β ) of benznidazole when coadministered with itraconazole were observed. The parameters area under the curve (AUC 0- t ), area under the curve extrapolated to infinity (AUC 0-∞ ), time to maximum concentration of drug in serum ( T max ), and clearance (CL) for benznidazole were not significantly different in this therapeutic regime. None of the evaluated parameters for ITC demonstrated a significant difference between isolated and associated administration. These results suggest that the main effect of this interaction leads to accumulation of benznidazole in the biological system. This effect may contribute to the improved therapeutic efficacy of this combination of drugs, in addition to synergism of the different mechanisms of action of benznidazole and itraconazole against Trypanosoma cruzi in vivo .